1 Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nature Reviews Cancer 16, 494 (2016).
2 Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. New England Journal of Medicine 373, 1541-1552 (2015).
3 Kozlowski, P. et al. High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper‐CVAD chemotherapy in S weden. European journal of haematology 92, 377-381 (2014).
4 Pui, C.-H., Relling, M. V. & Downing, J. R. Acute lymphoblastic leukemia. New England Journal of Medicine 350, 1535-1548 (2004).
5 Trinquand, A. et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. Journal of clinical oncology 31, 4333-4342 (2013).
6 Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology 12, 269-281 (2012).
7 Grupp, S. A. et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal of Medicine 368, 1509-1518 (2013).
8 Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine 377, 2531-2544 (2017).
9 Alcantara, M., Tesio, M., June, C. H. & Houot, R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 32, 2307-2315 (2018).
10 Cooper, M. L. et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32, 1970-1983 (2018).
11 Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes. The Journal of clinical investigation 127, 3462-3471 (2017).
12 Scarfò, I. et al. Anti-CD37 chimeric antigen receptor T cells are active against B-and T-cell lymphomas. Blood 132, 1495-1506 (2018).
13 Perera, L. P. et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T‐cell malignancies. American journal of hematology 92, 892-901 (2017).
14 Maciocia, P. M. et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nature medicine 23, 1416 (2017).
15 Pinz, K. et al. Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells. Leukemia 30, 701-707 (2016).
16 Mamonkin, M., Rouce, R. H., Tashiro, H. & Brenner, M. K. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983-992 (2015).
17 Sánchez-Martínez, D. et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 133, 2291-2304 (2019).
18 Png, Y. T. et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood advances 1, 2348-2360 (2017).
19 Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285-296 (2017).
20 Schenkel, A. R., Mamdouh, Z., Chen, X., Liebman, R. M. & Muller, W. A. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nature Immunology 3, 143-150 (2002).
21 Pasello, M., Manara, M. C. & Scotlandi, K. CD99 at the crossroads of physiology and pathology. Journal of Cell Communication and Signaling 12, 55-68 (2018).
22 Zhang, P. J. et al. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases. Modern pathology 13, 452-458 (2000).
23 Dworzak, M. N. et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia 18, 703-708 (2004).
24 Rocchi, A. et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. The Journal of clinical investigation 120, 668-680 (2010).
25 Edlund, K. et al. CD99 is a novel prognostic stromal marker in non‐small cell lung cancer. International journal of cancer 131, 2264-2273 (2012).
26 Cardoso, L. C. et al. CD99 expression in glioblastoma molecular subtypes and role in migration and invasion. International journal of molecular sciences 20, 1137 (2019).
27 Wilkerson, A. E., Glasgow, M. A. & Hiatt, K. M. Immunoreactivity of CD99 in invasive malignant melanoma. Journal of cutaneous pathology 33, 663-666 (2006).
28 Chung, S. S. et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Science translational medicine 9 (2017).
29 Manara, M. C., Pasello, M. & Scotlandi, K. CD99: a cell surface protein with an oncojanus role in tumors. Genes 9, 159 (2018).
30 Fujiwara, K., Masutani, M., Tachibana, M., Okada, N. J. B. & communications, b. r. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. 527, 350-357 (2020).
31 Drent, E. et al. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy 25, 1946-1958 (2017).
32 Drent, E. et al. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells. Clinical Cancer Research 25, 4014, doi:10.1158/1078-0432.CCR-18-2559 (2019).
33 Arcangeli, S. et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. 25, 1933-1945 (2017).
34 Srivastava, S. & Riddell, S. R. J. T. i. i. Engineering CAR-T cells: design concepts. 36, 494-502 (2015).
35 Dvinge, H. et al. Sample processing obscures cancer-specific alterations in leukemic transcriptomes. 111, 16802-16807 (2014).
36 Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics 49, 1211-1218 (2017).
37 Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nature Reviews Clinical Oncology 15, 47-62 (2018).
38 Gomes-Silva, D. et al. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Molecular Therapy 27, 272-280 (2019).
39 Havugimana, P. C. et al. A census of human soluble protein complexes. 150, 1068-1081 (2012).
40 Vetrie, D., Helgason, G. V. & Copland, M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer 20, 158-173 (2020).
41 Thomas, D. & Majeti, R. Biology and relevance of human acute myeloid leukemia stem cells. Blood 129, 1577-1585 (2017).
42 Chung, S. S. et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci Transl Med 9, doi:10.1126/scitranslmed.aaj2025 (2017).
43 Inoue, A. et al. Current and future horizons of patient-derived xenograft models in colorectal cancer translational research. Cancers 11, 1321 (2019).
44 Wang, D. et al. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients. 10, 1-4 (2020).
45 Martinez, M. & Moon, E. K. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol 10, 128 (2019).
46 Morgan, R. A. et al. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy 18, 843-851 (2010).
47 Parker, K. R. et al. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell 183, 126-142.e117 (2020).
48 Alvi, R. M. et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). Journal of the American College of Cardiology 74, 3099-3108 (2019).
49 Richman, S. A. et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. 6, 36-46 (2018).
50 Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. 19, 3153-3164 (2013).
51 Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. 75, 3505-3518 (2015).
52 Castellarin, M. et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. 5 (2020).
53 Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. 25, 1408-1414 (2019).
54 Verra, W. C. et al. Myeloid sarcoma presenting as a recurrent, multifocal nerve root entrapment syndrome. Journal of Neuro-Oncology 91, 59 (2008).
55 Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nature Medicine 25, 1341-1355 (2019).